logo
Apple just spent $500 million to source a material that's critical for iPhones from the US

Apple just spent $500 million to source a material that's critical for iPhones from the US

CNN5 hours ago
Apple is investing $500 million in a deal with US rare earths company MP Materials as the iPhone maker faces pressure from President Donald Trump to produce its popular smartphones domestically.
As part of the partnership announced on Tuesday, Apple committed to buying rare earth magnets directly from MP Materials to help bolster its US supply chain. Apple will also collaborate with the company on a new recycling line in California, which will repurpose recycled rare earth materials to use in Apple products.
The move is part of a $500 billion investment Apple announced earlier this year to expand its US operations as the Trump administration pushes to onshore technology manufacturing and reduce reliance on China. Rare earths, which are critical for everything from smartphones to TVs and military jets, have been a key bargaining chip in trade talks between Washington and Beijing. That's because China controls nearly all rare earths processing.
'American innovation drives everything we do at Apple, and we're proud to deepen our investment in the US economy,' Apple CEO Tim Cook said in a press release. 'Rare earth materials are essential for making advanced technology, and this partnership will help strengthen the supply of these vital materials here in the United States.'
MP Materials' facility in Fort Worth, Texas, will create new magnet manufacturing lines specifically for Apple products. Shipments are expected to begin in 2027 and will eventually support 'hundreds of millions of Apple devices,' according to MP Materials. The materials will be delivered throughout the United States and around the world.
Apple says the expansion will create dozens of new jobs. Both companies will also provide training to develop a US workforce for magnet manufacturing.
China has a virtual monopoly on rare earth elements, which are critical components for everyday products from smartphones to wind turbines to LED lights and flat-screen TVs. They're also crucial for batteries in electric vehicles as well as MRI scanners and cancer treatments.
The name rare earths is also a bit of a misnomer. The materials are found throughout the Earth's crust but are difficult and costly to extract and process. China has the only equipment needed to process some of the various elements and currently controls 92% of the global output in the processing stage.
While the MP Materials deal could help Apple curry favor with Trump amid tariff threats, it also aligns with Apple's efforts to incorporate more recycled materials into its products – a plan already in place long before Trump took office.
The iPhone 16e, which launched earlier this year, includes 30 percent recycled content, for example. Apple says it uses recycled rare earths in its major products, including in magnets found in the latest iPhones, iPads, Apple Watches, MacBook and Mac models.
The Trump administration has been pushing for Apple and other tech giants to produce their products in the United States rather than rely on assembly facilities and supply chain operations largely located in China, India and Vietnam.
'I have long ago informed Tim Cook of Apple that I expect their iPhone's that will be sold in the United States of America will be manufactured and built in the United States, not India, or anyplace else,' Trump posted on Truth Social in May. 'If that is not the case, a Tariff of at least 25% must be paid by Apple to the U.S.'
Apple hasn't discussed plans to move iPhone manufacturing to the US, and doing so seems unlikely. That's because it would require the tech giant to upend how it builds its most lucrative product.
Critically, Apple and MP Manufacturing's collaboration involves developing the talent pool needed for magnet manufacturing. That's part of the reason why it's so challenging to move iPhone production to the United States – America lacks the highly specialized labor required to do so, experts have said.
'The expertise to make each of the components is something that has to be worked on for a long period of time,' David Marcotte, senior vice president at international market research company Kantar, previously told CNN.
Cook has also spoken about the labor gap in the past, describing the workforce in China as being a combination of 'craftsman' skills, 'sophisticated robotics' and 'the computer science world' when speaking at a Fortune Magazine event in 2017.
But the commitment to invest in US-sourced rare earths is likely to please Trump. The president has touted Apple's previous investment announcement as a victory in his efforts to boost American manufacturing.
Apple is just one of many tech giants that have expanded their American footprint over the past several months. Texas Instruments committed $60 billion to make semiconductors in the United States in June, and Taiwanese chipmaking giant TSMC invested $100 billion in US manufacturing in March. Leading AI chipmaker Nvidia also said it would build its supercomputers in the United States in April.
– CNN's Chris Isidore contributed to this report
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

Yahoo

time15 minutes ago

  • Yahoo

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.

San Mateo County Sheriff Christina Corpus in court over misconduct accusation
San Mateo County Sheriff Christina Corpus in court over misconduct accusation

CBS News

time20 minutes ago

  • CBS News

San Mateo County Sheriff Christina Corpus in court over misconduct accusation

San Mateo County Sheriff Christina Corpus made her first court appearance after a civil grand jury accused her of misconduct. Corpus was at the Redwood City courthouse Tuesday morning for a hearing that only lasted several minutes. The sheriff did not speak, but through her attorneys denied the accusations against her. Last month, the county's civil grand jury accused Corpus of one count of conflict of interest over the hiring of Victor Aenlle, whom she allegedly had a close personal relationship with. The grand jury also accused the sheriff of three counts of retaliation following the termination of Assistant Sheriff Ryan Monaghan, the transfer of Capt. Brian Phillip and the arrest of Deputy Carlos Tapia, president of the Deputy Sheriff's Association. Thomas Mazzucco, Corpus' attorney, had previously said the civil grand jury's accusations were "related to politically motivated complaints by the upper echelons and union leadership" at the sheriff's office. Corpus has been facing months of scrutiny and calls to resign following the release of an independent report by retired judge LaDoris Cordell into allegations of abuse of power at the sheriff's office. The report prompted the San Mateo County Board of Supervisors to call for a special election in March to temporarily amend the charter to remove a sheriff from office for cause. Eighty-four percent of voters approved the amendment, which is also known as Measure A. Last month, the board initiated the process to remove Corpus from office, a process that is expected to take several months. If found guilty of the grand jury's accusations, Corpus faces removal along with potential penalties that could permanently bar her from seeking an elected position in the state. Corpus' next court appearance is scheduled for July 21.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store